EXEL analyst estimates
Exelixis (EXEL) analyst ratings, the average price target and its range, and every firm's latest call.
EXEL analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 30, 2026 | BMO Capital | Exelixis (EXEL) PT Raised to $60 at BMO Capital | $60.00 |
| Oct 9, 2026 | RBC Capital | Exelixis price target raised to $51 from $45 at RBC Capital | $51.00 |
| Oct 8, 2026 | RBC Capital | Exelixis price target lowered to $45 from $46 at RBC Capital | $45.00 |
| Aug 18, 2026 | BMO Capital | BMO starts Exelixis at Market Perform into patent cliff | $54.00 |
| Aug 6, 2026 | Truist Financial | Exelixis price target lowered to $52 from $56 at Truist | $52.00 |
| Aug 6, 2026 | Leerink Partners | Leerink downgrades Exelixis to Market Perform following Q2 results | $52.00 |
| Aug 3, 2026 | UBS | Exelixis (EXEL) Reiterated at Market Outperform by Citizens Amid Handa Patent Suit | $55.00 |
| Jul 23, 2026 | Morgan Stanley | Exelixis price target raised to $53 from $50 at Morgan Stanley | $53.00 |
| Jul 14, 2026 | Barclays | Exelixis price target raised to $49 from $45 at Barclays | $49.00 |
| Jul 13, 2026 | Wells Fargo | Exelixis price target raised to $49 from $40 at Wells Fargo | $49.00 |
| Jul 7, 2026 | RBC Capital | Exelixis price target raised to $46 from $43 at RBC Capital | $46.00 |
| Jul 2, 2026 | H.C. Wainwright | H.C. Wainwright Reiterates Buy Rating on Exelixis (EXEL) | $56.00 |
| Jul 2, 2026 | UBS | Exelixis price target raised to $52 from $43 at UBS | $52.00 |
| Jun 25, 2026 | Truist Financial | Truist Securities Assumes Exelixis (EXEL) at Hold | $54.00 |
| Apr 20, 2026 | Barclays | Exelixis price target raised to $45 from $44 at Barclays | $45.00 |
- 12 firms rate EXEL: 3 buy, 9 hold, 0 sell.
- The average price target is $53.00 from 9 analysts, from $49.00 to $60.00.
Updated 2026-11-02 17:51 UTC